Raymond James Financial
LXEO icon

Raymond James Financial’s Lexeo Therapeutics LXEO Stock Holding History

Raymond James Financial’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Buy
117,388
+101,803
+653% +$551K ﹤0.01% 4441
2026
Q1 		$89.5K Buy
15,585
+3,047
+24% +$21.6K ﹤0.01% 5057
2025
Q4 		$125K Buy
+12,538
New +$114K ﹤0.01% 4894

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Raymond James Financial's LXEO Position: Q2 2026 in Review

Raymond James Financial increased its Lexeo Therapeutics (LXEO) stake by 653% in Q2 2026, buying an estimated $551K and bringing the position to 117,388 shares worth $546K. The position accounts for ﹤0.01% of the portfolio, ranked #4441.

Raymond James Financial first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Raymond James Financial held 117,388 shares of Lexeo Therapeutics worth $546K as of Q2 2026.
  • Raymond James Financial bought 101,803 Lexeo Therapeutics shares in Q2 2026, an estimated $551K.
  • Lexeo Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4441 holding.
  • Raymond James Financial first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.